- TOTAL30 for Astigmatism, the first and only reusable Water
Gradient toric lens, is now available nationwide in the U.S.
- Alcon highlights the expansion of its toric lens portfolio with
latest innovations, including DAILIES TOTAL1 for Astigmatism and
PRECISION1 for Astigmatism, to be showcased
- Clinical data presentations to highlight efficacy of Alcon’s
ocular health and dry eye portfolios
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will unveil its latest
innovations and expansive suite of vision care products at the SECO
International meeting in Atlanta, Georgia. Alcon will debut
TOTAL30® for Astigmatism, the first and only reusable Water
Gradient toric lens on the market,1 now available to Eye Care
Professionals (ECPs) across the U.S. In addition to showcasing its
latest innovations, Alcon will present its newest clinical data and
research findings across its vision care, dry eye, allergy and
ocular health portfolios.
“Alcon is thrilled to be celebrating 100 years of SECO,” said
Sean Clark, General Manager, U.S. Vision Care, Alcon. “This year,
we have all the more reason to celebrate with the launch of TOTAL30
for Astigmatism, a lens that is paving the way for technological
development within the industry. From enhancing ocular health
categories to changing the toric lens landscape, Alcon endeavors to
aid ECPs in their mission to provide the best possible care for
their patients.”
Alcon Sets New Industry Standard with Debut of First and Only
Reusable Water Gradient Toric Lens, TOTAL30 for Astigmatism
Alcon will launch its premium one-of-a-kind reusable toric lens,
TOTAL30 for Astigmatism, featuring Alcon’s proprietary Water
Gradient and Celligent® Technologies, which allows the lens to
mimic the structure of the ocular surface.2 The innovation follows
recent findings that indicate that 66% of contact lens users wear
weekly or monthly lenses3 and 56% of monthly wearers experience eye
health problems, including discomfort, dryness and build-up
issues.4 However, 80% of contact lens patients would change lenses
if a more comfortable one was available.5 TOTAL30 for Astigmatism,
the first and only of its kind in the market, simultaneously serves
the rapidly expanding astigmatic market segment and those whose
lifestyles position them within the reusable lens category. The
lens joins the growing ranks of Alcon’s suite of toric options,
including DAILIES TOTAL1® for Astigmatism and PRECISION1® for
Astigmatism.
During SECO, Alcon will showcase an extensive collection of the
latest clinical research findings on TOTAL30 for Astigmatism,
illustrating the lens’ exceptional performance across categories
such as comfort, stability, visual acuity, and so much more, in
addition to the science behind Alcon’s Water Gradient and Celligent
Technologies.
Attendees can also join Alcon in unique experiences, including a
TOTAL30 for Astigmatism Try-On Event and live demos for Alcon’s
digital ordering platform, MARLO. Alcon will also share its plans
to expand MARLO to further drive connection between ECPs and their
patients while providing greater access to eye care in the U.S.
Data Bolsters Efficacy of Alcon’s Dry Eye and Ocular Health
Portfolio Offerings
Alcon’s presence at SECO coincides with the 20th anniversary of
Systane®, where Alcon will be highlighting findings on the
performance and efficacy of the company’s dry eye and ocular health
offerings including SYSTANE® HYDRATION Preservative-Free (PF),
Pataday® Twice Daily Relief, Pataday® Once Daily Relief, and
Pataday® Once Daily Relief Extra Strength.
The ocular health data focuses on the benefits of Pataday’s
dual-action formula and affirms the effectiveness of utilizing two
mechanisms of action to provide ocular allergy itch relief:
antihistamine and mast cell stabilization.
The research findings on SYSTANE HYDRATION PF highlight the
product’s Hydroboost technology to restore moisture and serve as a
protectant against irritation and provide relief from dry eye
symptoms.6
Visit Alcon booth #1138 for refreshments, samples of SYSTANE
HYDRATION PF, Pataday, and TOTAL30 for Astigmatism, and literature
on Alcon’s products.
Contact lenses are Rx only. Please see product instruction for
full wear, care and safety information.
For more information on the products, Alcon’s newest data and
programs featured in the release, visit
https://www.myalcon.com/professional/events/SECO2023/.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References
- ANGELINI - Viscoelasticity and mesh-size at the surface of
hydrogels - ARVO abstract (v1.0).
- Scanning transmission electron microscopy of lehfilcon A
contact lens and human corneal surface; Alcon data on file,
2020.
- Ipsos 2022 Consumer Brand Health Tracker.
- Multi-Sponsor Survey 2022 Study of U.S. Contact Lens
Market.
- Edelman TOTAL30 research.
- Rangarajan R, Kraybill B, Ogundele A, Ketelson H. Effects of a
Hyaluronic Acid/Hydroxypropyl Guar Artificial Tear Solution on
Protection, Recovery, and Lubricity in Models of Corneal
Epithelium. J Ocul Pharmacol Ther. 2015;31(8):491-497.
Trademarks are the property of their respective owners.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228006502/en/
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com Investor
Relations Allen Trang + 41 589 112 110 (Geneva) + 1 817
615 2789 (Fort Worth) investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From May 2024 to Jun 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2023 to Jun 2024